Cargando…

Risankizumab: COVID-19: case report

Detalles Bibliográficos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2021
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7954672/ http://dx.doi.org/10.1007/s40278-021-92530-6

Ejemplares similares

Rapid Response of Palmoplantar Psoriasis to Risankizumab: A Case Report
por: Al Muqrin, Abdullah Muqrin, et al.
Publicado: (2022)

Erythrodermic Psoriasis Managed with Risankizumab
por: Alajlan, Abdulmajeed, et al.
Publicado: (2022)

A case of nail psoriasis improved with treatment by risankizumab
por: AlAjlan, Abdulmajeed, et al.
Publicado: (2022)

Rapidly and successful improvement of nail psoriasis with risankizumab
por: Orsini, Diego, et al.
Publicado: (2023)

Risankizumab: Daily Practice Experience of High Need Patients
por: Brunasso, Alexandra M. G., et al.
Publicado: (2023)

Mycosis fungoides diagnosed after exposure to risankizumab for psoriasis
por: Fahmy, Lauren M., et al.
Publicado: (2023)

Risankizumab for psoriasis
Publicado: (2020)

Risankizumab-Aggravated Crusted Scabies in a Patient with Down Syndrome
por: Senterre, Yseult, et al.
Publicado: (2020)

Successful treatment of psoriasis with risankizumab in a patient with telangiectasia macularis eruptiva perstans
por: Barber, Cara, et al.
Publicado: (2022)

New-onset systemic lupus erythematous in a patient receiving risankizumab for psoriasis
por: Barber, Cara, et al.
Publicado: (2022)

Use of risankizumab in two HIV-positive patients with psoriasis
por: Maliyar, Khalad, et al.
Publicado: (2023)

Successful Treatment of Pityriasis Rubra Pilaris with Risankizumab in Children
por: Kołt-Kamińska, Marta, et al.
Publicado: (2023)

A Case of Recalcitrant Circinate Generalized (Lapière) Psoriasis Successfully Treated with Risankizumab
por: Ruggiero, Angelo, et al.
Publicado: (2022)

Risankizumab for the Treatment of Palmoplantar Pustular Psoriasis: a Report of Two Cases
por: Gargiulo, Luigi, et al.
Publicado: (2023)

Nivolumab-induced psoriasis successfully treated with risankizumab-rzaa in a patient with stage III melanoma
por: Glinos, George D., et al.
Publicado: (2021)

Meta‐Analyses of Clinical Efficacy of Risankizumab and Adalimumab in Chronic Plaque Psoriasis: Supporting Evidence of Risankizumab Superiority
por: Witjes, Han, et al.
Publicado: (2019)

Palmoplantar Psoriasis Successfully Treated With Risankizumab
por: Alajlan, Abdulmajeed M, et al.
Publicado: (2021)

Risankizumab in the treatment of psoriasis – literature review
por: Banaszczyk, Katarzyna
Publicado: (2019)

Rapid and sustained remission of synovitis, acne, pustulosis, hyperostosis, and osteitis (SAPHO) syndrome with IL-23p19 antagonist (risankizumab)
por: Flora, Akshay, et al.
Publicado: (2021)

Asymptomatic SARS-CoV2 infection in a patient receiving risankizumab, an inhibitor of interleukin 23
por: Ward, Madison, et al.
Publicado: (2020)

Efficacy and Safety of Risankizumab in Hidradenitis Suppurativa: A Case Series
por: REPETTO, Federica, et al.
Publicado: (2022)

Clinical Pharmacokinetics and Pharmacodynamics of Risankizumab in Psoriasis Patients
por: Pang, Yinuo, et al.
Publicado: (2019)

Risankizumab: an anti-IL-23 antibody for the treatment of psoriasis
por: Haugh, Isabel M, et al.
Publicado: (2018)

Risankizumab: A Review in Moderate to Severe Plaque Psoriasis
por: Blair, Hannah A.
Publicado: (2020)

Clinical Evaluation of Risankizumab-rzaa in the Treatment of Plaque Psoriasis
por: Reddy, Vidhatha, et al.
Publicado: (2020)

Successful treatment of a refractory pyoderma gangrenosum with risankizumab
por: Burgdorf, Birte, et al.
Publicado: (2020)

Correction to: Risankizumab: A Review in Moderate to Severe Plaque Psoriasis
por: Blair, Hannah A.
Publicado: (2020)

Risankizumab for the Treatment of Moderate to Severe Plaque Psoriasis in the Russian Federation
por: Odnopozova, Liudmila, et al.
Publicado: (2022)

Eruptive lentiginosis in resolving plaque psoriasis during treatment with risankizumab
por: Palmisano, Gerardo, et al.
Publicado: (2023)

Spotlight on risankizumab and its potential in the treatment of plaque psoriasis: evidence to date
por: Machado, Álvaro, et al.
Publicado: (2018)

Adverse events with risankizumab in the real world: postmarketing pharmacovigilance assessment of the FDA adverse event reporting system
por: Shu, Yamin, et al.
Publicado: (2023)

Risankizumab for Plaque and Guttate Psoriasis in a Patient with IgA-Related Glomerulonephritis
por: Dattola, Annunziata, et al.
Publicado: (2021)

Guselkumab, Risankizumab, and Tildrakizumab in the Management of Psoriasis: A Review of the Real-World Evidence
por: Ruggiero, Angelo, et al.
Publicado: (2022)

Population Pharmacokinetics and Exposure–Response Analyses for Risankizumab in Patients with Active Psoriatic Arthritis
por: Thakre, Neha, et al.
Publicado: (2022)

Risankizumab shows high efficacy and maintenance in improvement of response until week 52
por: Mastorino, Luca, et al.
Publicado: (2022)

Real-life Effectiveness and Safety of Risankizumab in Moderate-to-severe Plaque Psoriasis: A 40-week Multicentric Retrospective Study
por: BORRONI, Riccardo G., et al.
Publicado: (2021)

Clinical Evaluation of Risankizumab in the Treatment of Adults with Moderately to Severely Active Crohn’s Disease: Patient Selection and Reported Outcomes
por: Horst, Sara, et al.
Publicado: (2023)

InflammamiR-146a and -155 Plasma Levels are Associated with Clinical Efficacy of Risankizumab Treatment in Psoriatic Patients: Pilot Study
por: Diotallevi, Federico, et al.
Publicado: (2023)

The effect of risankizumab on achieving minimal clinically important differences in patient‐reported outcomes in patients with psoriatic arthritis: results from KEEPsAKE 1 and 2
por: Kristensen, L.E., et al.
Publicado: (2022)

Risankizumab for the Treatment of Moderate-to-Severe Psoriasis: Real-Life Multicenter Experience from the Czech Republic
por: Gkalpakiotis, Spyridon, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ieomakpd6lg922brt49a0d8vtm